MIGRAINE Relief for Kids is Finally Here!
Migraine is a complex neurological disease that extends far beyond a simple headache. It is a common, often hereditary condition that affects millions globally, including a significant population of children and adolescents. Approximately one in ten children in the United States suffers from migraines, a condition that can severely disrupt their daily lives, impacting school attendance, participation in sports, and overall family well-being (1). For parents, the experience of watching a child struggle with debilitating pain, often accompanied by nausea, vomiting, and light sensitivity, can be a source of constant worry and stress (1).
The good news is that a new era of targeted, preventive treatment has arrived, offering significant hope and a dramatically improved quality of life for young migraine sufferers.
A New Dawn in Pediatric Migraine Prevention
The recent approval of a new class of preventive medications marks a revolutionary shift in how pediatric episodic migraine is managed. These treatments are the first to be specifically designed to target the underlying biological mechanism of migraine, rather than being repurposed from drugs for other conditions (4).
The impact of this breakthrough is profound. For children who previously experienced frequent, debilitating attacks—such as a child whose migraines were reduced from six to ten per month to only about two per month—this new treatment offers freedom from constant pain and anxiety (1). This targeted approach allows children to return to normal activities, free from the shadow of their next migraine.
Special Section: AJOVY® (fremanezumab-vfrm)
AJOVY (fremanezumab-vfrm) is a prescription medicine used for the preventive treatment of migraine. It is approved for use in adults with migraine and, crucially, has received an expanded indication for children and adolescents aged 6 to 17 years who suffer from episodic migraine and weigh at least 99 pounds (45 kg) (2).
History and Mechanism of Action
The development of AJOVY represents a pivotal moment in migraine research, moving treatment away from broad-spectrum drugs to a highly specific, targeted therapy. AJOVY belongs to a class of medications known as Calcitonin Gene-Related Peptide (CGRP) inhibitors.
CGRP is a protein that plays a central role in the transmission of pain signals during a migraine attack (4). Researchers have identified that CGRP is critical in generating and maintaining the headache associated with migraine. AJOVY is a monoclonal antibody that works by directly targeting and neutralizing the CGRP molecule itself, thereby interrupting the pain pathway before a migraine can fully develop (2) (4).
AJOVY was initially approved for adults in September 2018 (4) and received its expanded indication for pediatric episodic migraine in August 2025 (5). It offers flexible dosing options, administered as a single subcutaneous injection either monthly or as three injections once every three months (quarterly) (2).
Improvement Over Existing Treatments
AJOVY and other CGRP inhibitors represent a significant improvement over previous generations of migraine treatments, which were often associated with poor tolerability and significant side effects (4).
Feature | Previous Preventive Treatments (e.g., Beta-blockers, Anticonvulsants) | AJOVY (CGRP Inhibitor) |
Mechanism | Repurposed from other conditions (e.g., hypertension, epilepsy) (3) | Specifically designed to target the CGRP pathway (4) |
Tolerability | Often associated with poor tolerability and systemic side effects (e.g., fatigue, weight change) (4) | Generally very favorable, with minimal organ toxicity or drug interactions (4) |
Side Effects | Wide range of systemic side effects (3) | Primarily localized injection site reactions (4) |
Target | Broad-spectrum, non-specific action (3) | Highly targeted, interrupting the core migraine pain signal (4) |
A Brief History of Migraine Treatment
The quest to treat migraine is ancient, with the first known mention of the condition appearing in ancient Egyptian medical documents dating back to 1550 BC (3). However, modern pharmacological treatment has evolved through distinct phases:
- 1920s: Ergots The first modern medication for acute migraine, ergotamine, became available in 1926 (3). Ergots work by increasing serotonin levels and reducing inflammation, but they also constrict blood vessels, making them unsuitable for patients with certain conditions like hypertension. They were also associated with significant side effects and a high risk of dependence (3).
- 1960s–1970s: Beta-blockers The discovery that the beta-blocker propranolol could reduce the frequency of migraine attacks was a significant milestone in 1966 (3). This led to its approval as the first medication specifically for the prevention of migraine, though it was originally developed for heart conditions (3).
- 1990s–2000s: Triptans The introduction of triptans, such as sumatriptan, in the early 1990s revolutionized the acute treatment of migraine (4). Triptans target serotonin receptors to constrict blood vessels and block pain pathways. While highly effective for stopping an attack, they were not designed for prevention and still carried side effects like chest tightness (4).
- 2010s–Present: CGRP Inhibitors The development of CGRP inhibitors, beginning with the first approvals in 2018, represents the first class of drugs developed specifically for migraine prevention based on a deep understanding of its pathophysiology (4). This new generation of treatment, including AJOVY, offers a highly effective and well-tolerated option that directly addresses the core mechanism of the disease.
References
(1) GoToHealth! (2025). Migraine RELIEF for Kids is Finally Here! [Video]. YouTube.
(2) Teva Pharmaceuticals. Preventive Treatment of Migraine | AJOVY® (fremanezumab-vfrm) injection. Ajovy.com.
(3) Pratt, E. (2024). The history of migraine treatments. Medical News Today.
(4) American Migraine Foundation. (2018). Migraine & Anti-CGRP Treatments. Americanmigrainefoundation.org.
(5) Teva Pharmaceuticals. (2025). FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm)… [Press Release]. IR.Tevapharm.com.
.
Listen on Podcast
Did you like your experience?
Please leave us a Testimonial HERE if you have a Google account.
Your word helps get our word out to more people.
Thank you in advance!!
